Skip to main content
Clinical Trials/NCT04727190
NCT04727190
Unknown
Not Applicable

The Efficacy and Safety of Transbronchial Cryobiopsy vs Forceps Biopsy in the Diagnosis of Lung Ground-glass Opacity: A Prospective, Randomized Controlled Trial

Shanghai Chest Hospital1 site in 1 country184 target enrollmentMarch 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lung Ground-Glass Opacity
Sponsor
Shanghai Chest Hospital
Enrollment
184
Locations
1
Primary Endpoint
Diagnostic yield
Last Updated
5 years ago

Overview

Brief Summary

The aim of this study is to investigate the difference of efficacy and safety between transbronchial cryobiopsy (TBCB) and transbronchial forceps biopsy (TBFB) in the diagnosis of lung ground-glass opacity.

Detailed Description

The conventional biopsy method for lung ground-glass opacity (GGO) diagnosis is to use disposable guided sheath (including biopsy forceps and cell brushes) which have some limitations, such as big physical damage, small biopsy tissue, etc. Cryobiospy is a new technique for biopsy developed in recent years which has many advantages over conventional biopsy, such as larger tissue, higher diagnosis yield, less complication, etc. The investigators will explore the efficacy and safety of cryobiospy vs. biopsy forceps in GGO diagnosis. The study is designed as a prospective, randomized controlled trial, 184 patients will be expected to enroll in the study and receive EBUS examination before biopsy to check whether the GGO lesions exist or not. This is a parallel-control study that patients with GGO lesions will be randomized to either TBCB group or TBFB group for biopsy. The primary aim is to compare the diagnostic yields of the two biopsy techniques. The secondary endpoint is to assess the tissue size, sampling time, number of sampling and the quality of specimen.

Registry
clinicaltrials.gov
Start Date
March 1, 2021
End Date
December 30, 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jiayuan Sun

Director, Department of Respiratory Endoscopy

Shanghai Chest Hospital

Eligibility Criteria

Inclusion Criteria

  • Male or female aged between 18 and
  • CT or other imaging examination suggest a tendency towards malignant GGO (size ≥ 8 mm). The ground glass composition is more than 50%.
  • Thin-slice CT scan with bronchial access or adjacent lesions.
  • Multidisciplinary assessment suggest that bronchopulmonary biopsy is needed to identify the pathological features of GGO.
  • It is suitable for pathological biopsy by transbronchial cryobiopsy or forceps biopsy.
  • Ability to read, understand and sign ICF.

Exclusion Criteria

  • Disseminated GGO, suspected of benign or infectious lesions.
  • Preoperative imaging examination showed that the biopsy lesion was adjacent to the middle or large vessels.
  • There are contraindications for bronchoscopy, such as irreparable coagulation dysfunction, severe cardiopulmonary insufficiency.
  • Intolerance or difficulty in cooperating with bronchoscopy, etc.
  • Routine bronchoscopic abnormalities, such as endoscopic lesions, external pressure, mucosal lesions, stenosis, hemorrhage, etc.
  • Vulnerable groups, such as pregnant women, etc.
  • Some other special situations investigator consider subjects are not suitable to participant in this study.

Outcomes

Primary Outcomes

Diagnostic yield

Time Frame: Up to 6 Months

Diagnostic yield of transbronchial cryobiopsy (TBCB) or transbronchial forceps biopsy (TBFB) for lung ground-glass opacity.

Secondary Outcomes

  • Tissue size(Up to 1 months)

Study Sites (1)

Loading locations...

Similar Trials